Keystone Symposia

This meeting took place in 2014

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

G Protein-Coupled Receptors: Structural Dynamics and Functional Implications (Z1)

Organizer(s) Christopher G. Tate and Fiona H. Marshall
March 30—April 4, 2014
Snowbird Resort • Snowbird, UT USA
Discounted Abstract Deadline: Dec 4, 2013
Abstract Deadline: Jan 8, 2014
Scholarship Deadline: Dec 4, 2013
Discounted Registration Deadline: Jan 30, 2014

Sponsored by Arena Pharmaceuticals, Inc. and Theravance, Inc.

Summary of Meeting:
G protein-coupled receptors are essential for intercellular communication in multicellular organisms and they are also the targets for many drugs already in use or under development, for the treatment of, for example, cardiovascular disease, asthma, cancer, neurological dysfunction and metabolic disorders. The field of GPCR biology has undergone a radical transformation with the structure determination of over 15 different GPCRs, including the first complex of an activated GPCR bound to a heterotrimeric G protein. This wealth of structural detail is now being translated into both a deeper understanding of GPCR function and into the development of new therapeutics. Structure is, however, only capable of defining atomic details of particular conformational states of a receptor. This meeting will focus on how an integration of structural data and information from experiments that study molecular dynamics in vitro, in vivo and in silico can be integrated to form an in-depth view of GPCR function. In addition, key therapeutic areas of cancer, inflammation and disorders of the central nervous system will be highlighted in relation to the development of novel therapeutics targeting GPCRs.

View Meeting Program


Keystone Symposia Future of Science Fund Scholarship Recipients

Alexey Bondar
Institute of Nanobiology and Structural Biology, Czech Republic

Maria H. Hauge
Copenhagen University, Denmark

Kamila M. Skieterska
Ghent University, Belgium

David M. Thal
Monash Institute of Pharmaceutical Sciences, Australia